TMTimothy H. McCalmont

Timothy H. McCalmont

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timothy H. McCalmont has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial Intelligence-based Diagnosis of Kaposi Sarcoma using Photographs in Dark-skinned Patients

    by Sarah J Coates, Feng Yang, Cody Hill, Zhiyun Xue, Sivaramakrishnan Rajaraman, Aggrey Semeere, Racheal Ayanga, Miriam Laker-Oketta, Helen Byakwaga, Robert Lukande, et al.

    Importance Advanced-stage disease at the time of diagnosis, with resultant high mortality, is among the most urgent issues for HIV-related Kaposi sarcoma (KS) in sub-Saharan Africa. Lack of access to skilled clinical personnel and histopathologic technology in the region contribute to diagnostic delays and advanced stage at diagnosis. Accordingly, new paradigms for KS diagnosis are needed. Objective To evaluate the accuracy of artificial intelligence (AI)-based interpretation of digital surface images of skin lesions to diagnose KS among dark-skinned patients in Uganda. Design Cross-sectional study of consecutive participants referred to skin biopsy services in Uganda because of clinical suspicion of KS. Lesions were photographed using a digital camera, and punch biopsies were obtained. Histopathologic interpretation was considered the gold standard. Using training (∼70% of images) and validation (∼10% of images) sets, we developed a prediction model using a rule-based combination of YOLO (You Only Look Once) version 5 and 8 object detection classifiers. Setting Free-of-charge skin biopsy services Participants Consecutive sample of 482 individuals were evaluated due to clinical suspicion of KS. Main Outcomes Sensitivity, specificity, positive and negative predictive value (with accompanying 95% confidence intervals) of the AI-based prediction model in a test set (∼20% of images). The accuracy of a dermatologist’s visual interpretation of images was also described. Results 472 participants (1385 images) were evaluable. Of these, 36% were female, median age was 34 years, and 94% had HIV; 332 had KS, and 140 had no KS by histopathology. In the test set, the AI-derived prediction model achieved 89% sensitivity (85%-94%) and 51% specificity (40%-61%) for diagnosing KS; positive predictive value was 81% (75%-86%) and negative predictive value was 67% (55%-78%). A dermatologist evaluating the same images, with emphasis on sensitivity, achieved sensitivity of 93% (89%-96%) and specificity of 19% (11%-28%). Conclusions and Relevance Among dark-skinned patients in Uganda with skin lesions suspicious for KS, evaluation of digital surface images by an AI-based prediction model produced moderate accuracy for diagnosing KS. While currently inadequate for clinical use, this inaugural assessment is sufficiently promising to justify evaluation of larger datasets and evolving technologies to determine if accuracy can be improved. Question Can an artificial intelligence (AI)-based prediction model be developed from digital images to accurately distinguish Kaposi sarcoma (KS) from non-KS in dark-skinned patients? Findings Evaluation of digital images of skin lesions from patients in Uganda by an AI-based prediction model produced moderate accuracy for diagnosing KS. Meaning In sub-Saharan Africa, where incidence and mortality from KS is high and delayed diagnosis is common due to limited specialized personnel and technical supplies, AI-based prediction models built on digital images taken of suspicious lesions may someday hasten KS diagnoses.


  • Histopathologic and genetic findings in atypical spindle cell/pleomorphic lipomatous tumors and atypical pleomorphic fibromas

    by Laleh Montaser Kouhsari, Philip E. LeBoit, Timothy H. McCalmont, Brian Hinds, Jeffrey P. North

    Background: Spindle cell lipomas, pleomorphic lipomas (SCL/PLs), and pleomorphic fibromas (PF) are tumors with loss of retinoblastoma (RB). The latest World Health Organization classification includes a category of atypical spindle cell/pleomorphic lipomatous tumors (ASPLT), which encompasses tumors in this spectrum that show atypical histopathologic features. We have observed PFs that show similar atypical features.Methods: Cases of SCL/PL and PF with atypical features were collected from tissue archives between 2010 and 2019. Genetic alterations were investigated using array comparative genomic hybridization (aCGH).Result: Of 15 cases found, most tumors were dermal based with fibrocytic or fibroadipocytic appearance and occasional lipoblasts. All cases had a high proliferation index with atypical mitotic figures in 71% of cases. Chromosome 13q loss was present in all cases with CGH data. Additional recurrent chromosomal losses included 17p, 16q, 17q, 20p, 4, and 10. No recurrence was found in limited follow‐up.Conclusions: ASPLTs are characterized by loss of RB, prominent nuclear pleomorphism, mitotic activity including atypical mitotic figures, and genomic instability with multiple chromosomal aberrations. A similar group of tumors with these histopathologic features lacks lipomatous differentiation, and we propose the diagnosis of atypical PF as a fibromatous variant of ASPLT. Limited clinical follow‐up appears benign.


  • An Evidence-Based Approach to Pediatric Melanonychia

    by Mary E. Lohman, Timothy H. McCalmont, Kelly M. Cordoro


  • BAP1‐inactivated melanocytic tumors show prominent centrosome amplification and associated loss of primary cilia

    by Julia Ye, Kathleen M. Sheahon, Philip E. LeBoit, Timothy H. McCalmont, Ursula E. Lang

    Background BRCA1-associated protein (BAP1) is a tumor suppressor whose loss is associated with various malignancies. The primary cilium is an organelle involved in signal transduction and cell cycle progression. Primary cilia have been shown to be absent in melanoma but retained to some extent in melanocytic nevi, and the severity of dysplasia influences the degree of cilia loss. Additionally, studies have revealed roles for BAP1 in centrosome and mitotic spindle formation. Because the primary cilium is nucleated on the mother centriole, we examined the connection between the presence of primary cilia and the formation of centrosomes in BAP1-inactivated melanocytic tumors (BIMTs). Methods We evaluated the cilia and centrosomes in eleven BIMTs and five conventional melanocytic nevi using immunofluorescence staining of acetylated alpha-tubulin and gamma tubulin. Results We found that, compared to nevi, BIMTs demonstrate loss of primary cilia and amplification of centrosomes. Occasional nevi also showed increased centrioles; however, these foci of amplification were more likely to be ciliated than those in BIMTs. Conclusions Although centrosome amplification does not absolutely correlate with loss of primary cilia in melanocytic neoplasms, absence of BAP1 exacerbates the phenotype. Moreover, aberrant centrosome and cilia formation are likely critical in the pathogenesis of other BAP1-inactivated tumors.


  • Fusion partners of NTRK3 affect subcellular localization of the fusion kinase and cytomorphology of melanocytes

    by Arnaud de la Fouchardière, Meng Kian Tee, Sandra Peternel, Manuel Valdebran, Daniel Pissaloux, Franck Tirode, Klaus J. Busam, Philip E. LeBoit, Timothy H. McCalmont, Boris C. Bastian, et al.


  • Ciliation Index Is a Useful Diagnostic Tool in Challenging Spitzoid Melanocytic Neoplasms

    by Ursula E. Lang, Rodrigo Torres, Christine Cheung, Eszter K. Vladar, Timothy H. McCalmont, Jinah Kim, Robert L. Judson-Torres


  • Genomic and Clinicopathologic Characteristics of PRKAR1A-inactivated Melanomas

    by Jarish N. Cohen, Iwei Yeh, Thaddeus W. Mully, Philip E. LeBoit, Timothy H. McCalmont

    Melanocytic tumors with inactivation of protein kinase A regulatory subunit-α (PRKAR1A) have large oval nuclei and intense pigmentation. Historically, these tumors have been categorized under various names, including epithelioid blue nevus, pigmented epithelioid melanocytoma (PEM) and animal-type melanoma. Although a subset of PEM harbor BRAF activating mutations and biallelic inactivation of PRKAR1A, there are only a few reports of melanomas, or of tumors with genomic alterations beyond those of PEMs. Herein, we describe the clinicopathologic and genetic features of 8 melanomas and tumors that lack PRKAR1α expression by immunohistochemistry but do not fit with conventional PRKAR1A-inactivated melanocytomas. These tumors tended to affect younger patients than conventional melanomas (median age=38 y) and presented as dark brown/black papules and nodules. Histopathologically, they demonstrated nodularity, sometimes in a background of conventional melanoma, and large vesicular nuclei with prominent nucleoli. With the exception of 1 case, the mitotic index was not significantly elevated. Immunohistochemically, all cases showed loss of PRKAR1α and of p16 expression. Seven tumors underwent massively parallel short read (next-generation) sequencing of a panel of 480 cancer-associated genes. Five tumors demonstrated truncating mutations of PRKAR1A and the 2 in which such mutations were not identified demonstrated loss of heterozygosity of the PRKAR1A locus. Four of the tumors harbored BRAF V600E mutations, and 1 harbored a FAM39B-BRAF gene fusion. Another harbored a GNA11 activating mutation. A MAP kinase activating mutation was not identified in the remaining case. Four tumors displayed TERT promoter mutations and chromosomal copy number changes supporting the diagnosis of melanoma. Two cases without these alterations and were classified as “high-grade PRKAR1A-inactivated melanocytomas”. The 1 case with widespread metastases demonstrated mutations in TP53 and RB1. Overall, we provide the first genetic characterization of PRKAR1A-inactivated melanomas, discuss the differential diagnosis of heavily pigmented epithelioid melanocytic neoplasms, and propose a new nomenclature for such tumors.


  • The Second Dimension—Integrating Calculated Tumor Area Into Cancer Diagnosis

    by Timothy H. McCalmont

    As a general principle, a key indicator of the prognosis of a given primary malignant tumor is its size. Simply put, at the time of cancer diagnosis, it is bett


  • Hypercellular Encapsulated Neuroma Imitating Desmoplastic Melanoma

    by Caitlin May, Philip LeBoit, Timothy McCalmont, Zsolt Argenyi

    Palisaded encapsulated neuromas (PENs) are benign cutaneous nerve sheath proliferations that typically occur as flesh-colored papules solitarily on the head and neck in adults, with a slight predilection for females. Histopathologically, they are partially or completely encapsulated intradermal nodules with Schwann cells and axons in fascicles separated by clefts. Although these features are often characteristic, the hypercellular variant of PEN can pose a diagnostic challenge in distinguishing between other cellular neural and melanocytic lesions. We herein report a case of hypercellular PEN, which showed striking similarity to desmoplastic melanoma.


  • Oncocytic Metaplasia in Melanocytic Tumors

    by Christine Ahn, Emily DeSantis, Timothy McCalmont

    Oncocytic metaplasia represents a histopathologic feature that can be observed in normal tissue such as salivary and lacrimal glands but may also constitute a degenerative metaplastic process as a result of repeated oxidative damage during cellular aging. Although cutaneous oncocytic metaplasia has been considered rare, the finding was seen in over one-third of melanocytic nevi prospectively evaluated, in one study. This case series reports on a small series of oncocytic melanocytic tumors, with the aim of describing this phenomenon in varied contexts and also describing the use of a mitochondria' antigen immunostain, which has not been previously reported.